NVNO - enVVeno Medical Corp

NVNO - enVVeno Medical Corp

https://www.envveno.com

Recent News

Powered by Alpha Vantage

NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve

Zacks Commentary • 3 weeks ago • score: -0.03

enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$5.70

52W Low

$0.76

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.88

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.87

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.45

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.84%

Institutions (25–75% balanced)

27.28%

Shares Outstanding

19,247,100

Float

17,800,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.20

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.65%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—